Subject: MJTV Expanding and Testing Lucrative Dronabinol Based Formulations

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
MJTV Expanding and Testing Lucrative Dronabinol Based Formulations
Hot Stock to WatchHot Stock to Watch

Company: Michael James Enterprises, Inc. (OTCQB: MJTV)


Price: 0.12

Change (%): + 0.00 (0.00)

Volume: 5,000
MJTV Chart

Michael James Enterprises Begins Research on MJ-391, a Dronabinol Based Product for the Treatment of Anorexia Nervosa

SHORT HILLS, NJ-(Marketwired - Aug 18, 2016) - Michael James Enterprises, Inc. (OTCQB: MJTV) is pleased to report that MJTV has begun research with a new Dronabinol based formulation, MJ-391 as a treatment for anorexia nervosa commonly called anorexia. MJTV now has two Dronabinol based formulations for two therapeutic treatments and will look to further expand its pipeline in the coming weeks and months.

Perhaps most convincingly, a 2014 study, published in the International Journal of Eating Disorders, was conducted on subjects with “severe” Anorexia Nervosa. Researchers administered Dronabinol to some subjects versus placebo to others, and found that those who received the cannabis-based treatment showed a significant weight gain compared to those who received the placebo. The study also noted that the medication was well tolerated and showed no serious adverse side effects.

MJTV previously completed pre-clinical trials on its Dronabinol plus formulation in the spring of 2016 with results that management believes to be much more effective than just Dronabinol alone for treating sleep apnea. Through internal research, MJTV changed the additional active ingredient that was added to the Dronabinol and has come up with a new formulation for the potential treatment of people with anorexia.

James Farinella, CEO of Michael James Enterprises, stated, “We are very excited about the current therapeutic offerings that we are developing. Just as exciting, we are very close to developing additional formulations that will increase our pipeline of products under development.”

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks